Beautiful Plants For Your Interior

The main downsides of taking a GLP-1 medication for weight loss are gastrointestinal side effects, loss of lean muscle along with fat, weight regain once you stop, a short list of rarer but serious risks on the FDA label, and cost. In the FDA label for Wegovy (semaglutide), 44% of treated patients reported nausea and 30% reported diarrhea, and in a body-composition substudy of the SURMOUNT-1 tirzepatide trial about 25% of the weight lost came from lean mass rather than fat. Most of these trade-offs are manageable, but two of them — dehydration and constipation — hinge directly on something people rarely plan for: how much water you actually drink.
That last point is why we cover GLP-1 medications on a water-quality site. The drugs slow how fast your stomach empties and turn down appetite, and many people find they drink less as they eat less, which also means less water from food. When nausea, vomiting, or diarrhea is added on top, fluid losses stack up quickly. Understanding the downsides means understanding the fluid side of them.
Some links below are affiliate links. If you buy through them we may earn a commission at no extra cost to you. See our Affiliate Disclosure.
The 6 real downsides of GLP-1 medications
1. Gastrointestinal side effects are common, not rare
This is the downside most people meet first. In the FDA prescribing information for Wegovy (semaglutide 2.4 mg), nausea was reported by 44% of treated patients versus 16% on placebo, vomiting by 24% versus 6%, diarrhea by 30% versus 16%, and constipation by 24% versus 11% (Table 3 of the label).
Tirzepatide (Zepbound, Mounjaro) shows a similar pattern. In SURMOUNT-1, adverse events led 4.3% to 7.1% of participants to stop treatment depending on dose, against 2.6% on placebo. For Wegovy, 6.8% of patients discontinued permanently because of adverse reactions versus 3.2% on placebo, with nausea, vomiting, and diarrhea the leading reasons.
The honest read: for most people these symptoms are worst during dose escalation and settle down. For a meaningful minority — roughly 1 in 15 — they are bad enough to end treatment.
2. Dehydration, and the kidney risk behind it
This is the downside that gets underestimated. The FDA prescribing information for semaglutide states that a majority of reported post-marketing acute kidney injury cases occurred in patients who had experienced nausea, vomiting, or diarrhea leading to volume depletion. In other words, the kidney events were largely a dehydration problem, not a direct drug-toxicity problem.
A pharmacovigilance analysis of FDA Adverse Event Reporting System data from 2004 through 2021, published in Frontiers in Endocrinology, identified 2,670 acute kidney injury cases associated with GLP-1 receptor agonists, with a hospitalization rate of 45.3% and a median time to onset of 63 days. These are voluntary reports, so they cannot establish how often this happens per patient — but they do tell you which mechanism keeps recurring.
FDA labeling advises clinicians to monitor kidney function in patients reporting reactions that could cause severe dehydration, particularly at initiation and dose escalation. That is the window to be deliberate about fluids.
We wrote a fuller breakdown of the warning signs in what happens if you don’t drink enough water on GLP-1, and a practical target-setting guide in how much water to drink on Zepbound.

3. You lose muscle along with fat
Weight loss is not the same as fat loss. A DXA body-composition analysis from the SURMOUNT-1 study, published in Diabetes, Obesity and Metabolism, found that participants in the pooled tirzepatide dose groups (124 people across the 5, 10, and 15 mg arms) lost 21.3% of body weight overall — a 33.9% reduction in fat mass and a 10.9% reduction in lean mass. About 75% of the weight lost was fat and 25% was lean tissue, and the authors report the same proportions in the placebo group, which lost far less weight overall.
Some lean-mass loss accompanies any substantial weight loss, including diet-only and surgical weight loss. But the pace matters. Resistance training and adequate protein are the standard counter-measures, and they are worth building in from week one rather than after the fact.
4. The weight comes back if you stop
The STEP 1 trial extension, published in Diabetes, Obesity and Metabolism, followed participants after semaglutide and the structured lifestyle program were both withdrawn. Mean weight loss at week 68 was 17.3% on semaglutide versus 2.0% on placebo. By week 120 — a year after withdrawal — the semaglutide group had regained 11.6 percentage points, leaving a net 5.6% below baseline. Roughly two-thirds of the loss came back.
Cardiometabolic improvements largely reverted toward baseline over that same period. STEP 4, published in JAMA, showed the flip side: participants who stayed on the drug after a 20-week run-in kept losing, while those switched to placebo regained steadily over the next 48 weeks. Tirzepatide shows the same pattern: in SURMOUNT-4, participants who lost an average of 20.9% over a 36-week open-label lead-in and were then switched to placebo regained 14.0% of their body weight over the next 52 weeks, while those who stayed on tirzepatide lost a further 5.5%.
The practical implication is that these are maintenance medications, not a course of treatment with an end date. The NIH’s NIDDK puts it plainly: after stopping any weight-management medication, you probably will regain some weight.
5. Rarer but serious labeled risks
These are uncommon, but they are on the label for a reason. The boxed warning comes first: in rodent studies, both semaglutide and tirzepatide caused dose- and duration-dependent thyroid C-cell tumors. Whether this translates to humans is unknown, and both drugs are contraindicated if you or a family member has had medullary thyroid carcinoma or if you have MEN 2.
The remaining warnings, as listed in the current prescribing information for each drug:
| Labeled warning | Zepbound (tirzepatide) | Wegovy (semaglutide) | What to watch for |
|---|---|---|---|
| Acute pancreatitis | Yes; 0.2% vs 0.2% on placebo in the pooled weight-loss trials | Yes | Severe, persistent abdominal pain, sometimes radiating to the back; stop the drug and seek care |
| Acute gallbladder disease | Yes; cholecystitis 0.7% vs 0.2% | Yes; gallstones 1.6% vs 0.7%, cholecystitis 0.6% vs 0.2% | Upper-right abdominal pain, fever, yellowing skin |
| Severe gastrointestinal reactions | Yes; 1.7–3.1% by dose vs 1% | Yes; 4.1% vs 0.9% | Not recommended with severe gastroparesis |
| Acute kidney injury from volume depletion | Yes | Yes | Vomiting, diarrhea, or not keeping fluids down |
| Serious hypersensitivity reactions | Yes | Yes | Swelling of the face or throat, trouble breathing, severe rash |
| Hypoglycemia | Yes | Yes | Higher risk with insulin or a sulfonylurea |
| Diabetic retinopathy complications | Yes (type 2 diabetes) | Yes (type 2 diabetes) | Vision changes if you have a history of retinopathy |
| Heart rate increase | Not a listed warning | Yes | Racing heartbeat at rest |
| Pulmonary aspiration under anesthesia or deep sedation | Yes | Yes | Tell your care team before any planned surgery or procedure |
| Reduced effect of oral contraceptives | Yes (drug interaction section) | Not listed | Use a non-oral or added barrier method for 4 weeks after starting and after each dose increase |
Labels have also been updated over time to reflect postmarketing gastrointestinal reports, including intestinal blockage. None of this is a reason to avoid the medication on its own. It is a reason to have the conversation with a prescriber rather than sourcing it from a website.
6. Cost and coverage
Branded weight-loss GLP-1s are expensive, and coverage is inconsistent. In KFF’s 2025 employer survey, 19% of large firms (200+ workers) offering health benefits covered GLP-1s for weight loss; among firms with 5,000+ employees, 43% covered them in their largest plan. In Medicare, Part D covers these drugs for indications such as type 2 diabetes, sleep apnea, and MASH, while use solely for weight management runs through CMS’s time-limited GLP-1 Bridge demonstration (July 2026 through December 2027). Since stopping brings the weight back, the cost question is an indefinite one, not a one-year one.
How to blunt the hydration-linked downsides
Two of the six downsides above — dehydration-linked kidney risk and constipation — respond directly to fluid intake. A few things that help:
- Drink on a schedule, not on thirst. With appetite turned down, it is easy to forget to drink. Sipping to a set routine works better than waiting to feel dry.
- Small volumes, spread out. Large boluses on a slow-emptying stomach make nausea worse. Frequent small amounts are better tolerated.
- Add electrolytes when you are losing fluid. If vomiting or diarrhea is in the picture, plain water alone replaces volume but not sodium and potassium. Our guide to electrolytes on GLP-1 medications covers when that applies, and we compared the options in electrolyte water vs regular water; a sugar-free electrolyte powder is the simplest way to do this without adding calories.
For the broader picture on fluids and weight loss, see our pillar guide to water for weight loss and GLP-1, and the first-month checklist in what I wish I knew before starting GLP-1.
Before you drink more, know what you’re drinking
If you’ve been increasing your water intake, it’s worth knowing what’s actually coming out of your tap. Your utility’s annual report covers the whole system average, not your house — and it says nothing at all about private wells or your own plumbing. A certified lab test gives you a full contaminant panel and, just as often, tells you your water is fine and you don’t need to buy anything.
Frequently Asked Questions
What is the biggest downside of GLP-1 medications?
For most people it is gastrointestinal side effects — nausea affected 44% of participants in the semaglutide weight-loss trials. But the downside with the longest tail is weight regain: the STEP 1 extension found roughly two-thirds of lost weight returned within a year of stopping.
Do GLP-1 drugs damage your kidneys?
The FDA label attributes the majority of reported post-marketing acute kidney injury cases to volume depletion from nausea, vomiting, or diarrhea — that is, to dehydration rather than direct kidney toxicity. Staying ahead of fluid losses is the practical protection. If you have existing kidney disease, this is a conversation to have with your prescriber before starting.
Why do GLP-1 medications cause constipation?
These drugs slow gastric emptying and gut motility, so stool spends longer in the colon and more water is reabsorbed from it. Constipation was reported by 24% of Wegovy-treated patients versus 11% on placebo in the FDA label. Fluid, gradual fiber increases, and movement are the usual first-line responses.
How much muscle do you lose on a GLP-1?
In the SURMOUNT-1 body-composition substudy, participants across the pooled tirzepatide doses lost 10.9% of lean mass alongside a 33.9% reduction in fat mass — about a quarter of total weight lost was lean tissue, the same proportion seen with placebo. Resistance training and adequate protein intake are the standard mitigations.
Will I regain the weight if I stop taking a GLP-1?
Most people regain a substantial share of it. In the STEP 1 extension, participants regained 11.6 of the 17.3 percentage points they had lost within a year of stopping the drug and the lifestyle program. NIDDK notes that regain after stopping any weight-management medication should be expected.
Does drinking more water reduce GLP-1 side effects?
Adequate fluid intake is standard clinical advice for managing the constipation and dehydration risk associated with these drugs, and dehydration is the mechanism the FDA links to reported kidney injury cases. It will not eliminate nausea, which is driven by the drug’s effect on gastric emptying, but it addresses the complications that follow from fluid loss.
Sources
- U.S. Food & Drug Administration via DailyMed — WEGOVY (semaglutide) Prescribing Information
- U.S. Food & Drug Administration via DailyMed — ZEPBOUND (tirzepatide) Prescribing Information (warnings, pancreatitis and gallbladder rates, oral contraceptive interaction, Study 4/SURMOUNT-4)
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), New England Journal of Medicine
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), New England Journal of Medicine
- Wilding JPH et al. — Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension, Diabetes, Obesity and Metabolism
- Rubino D et al. — Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4), JAMA
- Aronne LJ et al. — Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4), JAMA, 2024
- Look M et al. — Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study, Diabetes, Obesity and Metabolism
- Dong S, Sun C — Can GLP-1 receptor agonists cause acute kidney injury? Post-marketing pharmacovigilance analysis, Frontiers in Endocrinology
- National Institute of Diabetes and Digestive and Kidney Diseases (NIH) — Prescription Medications to Treat Overweight & Obesity
- KFF — 2025 Employer Health Benefits Survey news release (GLP-1 coverage for weight loss by firm size)
- Centers for Medicare & Medicaid Services — Medicare GLP-1 Bridge: Information for Part D Plans
Last updated October 31, 2026.
This article is for general information only and is not medical advice. GLP-1 medications are prescription drugs; decisions about starting, adjusting, or stopping one should be made with a licensed clinician who knows your history. See our Health Disclaimer.
[…] everything, and losing weight fast can cost lean tissue along with fat (we cover that trade-off in the downsides of GLP-1 medications). Second, the advisory suggests eating the protein-rich part of a meal first, so it does not get […]